Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Communiqué: big wins for obesity and sugar tax campaigners
This entry described a live ‘broadcast’meeting that provided education around excess steroid use, a standard treatment for ulcerative colitis. ... Meanwhile, Aurora Healthcare Communications’ Travel with IBD campaign for Japanese pharma group
Latest news
-
Trial data suggest Abivax’ drug may clear latent HIV
Those anti-inflammatory properties have encouraged Abivax to carry out a phase 2a trial of the drug in ulcerative colitis, with results expected in September.
-
AbbVie builds case for arthritis blockbuster-in-waiting upadacitinib
Meanwhile, following the same path as Xeljanz, upadacitinib is also being tested in a string of other indications, including psoriatic arthritis, Crohn’s disease, ulcerative colitis and atopic dermatitis.
-
Pfizer’s Xeljanz picks up a third indication in IBD
Pfizer’ s Xeljanz picks up a third indication in IBD. The JAK inhibitor can now treat US patients with ulcerative colitis. ... The twice-daily, orally administered drug is set to treat adult patients with moderately-severely active ulcerative colitis
-
Pfizer’s Xeljanz picks up a third indication in the US
The JAK inhibitor can now treat patients with ulcerative colitis. The US Food and Drug Administration (FDA) has given its seal of approval to Pfizer’s Xeljanz (tofacitinib), a JAK inhibitor ... The twice-daily, orally administered drug is set to treat
-
AbbVie’s upadacitinib aces phase III trial
even climb as high as $5bn at peak if it also shows its worth in follow-up indications like psoriatic arthritis, Crohn's disease, ulcerative colitis, ankylosing spondylitis and atopic dermatitis.
More from news
Approximately 19 fully matching, plus 106 partially matching documents found.
Latest Intelligence
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
-
Deal Watch January 2017
Assembly Biosciences. Allergan. Exclusive global licence . 2 pc candidates for ulcerative colitis (ABI-M201) and Crohn's disease plus 2 compounds for IBS.
-
Forging a path in specialty care
Adcetris (for Hodgkin Lymphoma), Entyvio (for ulcerative colitis and Crohn's Disease) and future compound Ninlaro (an oral protease inhibitor for relapsed/refractory multiple myeloma) which was approved by the FDA
-
Biosimilars - the same, but different?
The first months of 2015 also saw it approve Remsima and Inflectra for use on the NHS to treat moderately to severely active ulcerative colitis after the failure of conventional therapy.
More from intelligence
Approximately 0 fully matching, plus 12 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
AstraZeneca veteran Deborah Hartman joins Avaxia. Will lead the development of AVX-470 in ulcerative colitis. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
News: Research Partnership launches new patient report - Living with Ulcerative Colitis
News: Research Partnership launches new patient report - Living with Ulcerative Colitis. ... Living with UC is a quantitative study conducted online amongst 325 patients, including both adult and paediatric patients diagnosed with ulcerative colitis in 5
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017
Research Partnership has published a new Living with Ulcerative Colitis (UC) US market report for 2017. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 110 adult UC patients in the US.
-
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report
Research Partnership launches new patient Living with Ulcerative Colitis (UC) US report. ... Living with Ulcerative Colitis (UC) is a study conducted amongst 100 adult UC patients in the US.
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016. ... Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe.
-
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016
Research Partnership has published a new Living with Ulcerative Colitis (UC) market report for 2016. ... Ulcerative Colitis (UC) is a progressive and debilitating disease which affects between 2.5 to 3 million people in Europe.
More from PMHub
Approximately 5 fully matching, plus 2 partially matching documents found.
Featured jobs
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Business Unit Head, Medical Communications, London
-
Excellent package
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
-
Client Services Director - Med Comms
-
Great salary and bebefits
-
Healthcare PR Director
-
£100, 000 – £120, 000 benefits
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
-
Account Manager
-
£40, 000 - £45, 000 benefits
- Account Manager, Medical Communications and Marketing
-
£30, 000 – £40, 000 benefits and bonus
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Moving annual total (MAT)
- Roche keeps Venclexta train rolling with new leukaemia filing
- NHS England says yes to Roche's Hemlibra
- Daily Brief: Trump arrives in London, NICE says no to Darzalex, Pfizer backs down on prices
- Daily Brief: success for Pfizer and Lilly arthritis drug, Darzalex soars, IMI launches Accelerator
- Brexit rebels win vote on European Medicines Agency alignment
- Data Visualisation
- The True Potential of Mobile Health Tech
- NHS England to Vertex: come clean on Orkambi offer
- Novartis follows Pfizer and freezes US prices this year
PMHub
COUCH.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...
Latest intelligence
- Developing advocacy in the pharmaceutical industry.
- The importance of advocacy programmes...
- GDPR and events. What does the pharma industry need to know?
- Many people in the pharma industry still aren’t following the rules set out by the GDPR when it comes to running events and attending tradeshows. But with eye-watering fines for...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
Quick links
Infographics
